DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

计划入组 162 人 · 首次发布于 2022 年 6 月 13 日

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

计划入组 167 人 · 首次发布于 2025 年 3 月 3 日

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

计划入组 101 人 · 首次发布于 2020 年 3 月 31 日

TERN-501

TERN-301

TERN-800

Turn Therapeutics

Teon Therapeutics, Inc.

United States

JASPER THERAPEUTICS, INC

United States

Andelyn Biosciences Partners with Tern Therapeutics for Late-Stage Manufacturing of CLN2 Batten Disease Gene Therapy

Terns Pharmaceuticals Advances CML Drug TERN-701 and Obesity Treatment TERN-601 in Clinical Trials

Terns Pharmaceuticals' Oral GLP-1 Agonist TERN-601 Shows Promise in Phase 1 Obesity Trial